{"id":44640,"date":"2025-10-27T23:49:24","date_gmt":"2025-10-27T15:49:24","guid":{"rendered":"https:\/\/flcube.com\/?p=44640"},"modified":"2025-10-27T23:49:25","modified_gmt":"2025-10-27T15:49:25","slug":"grand-pharma-launches-gpn00884-clinical-trial-to-tackle-pediatric-myopia-progression","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44640","title":{"rendered":"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression"},"content":{"rendered":"\n<p>Grand Pharmaceutical Group Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/0512:HKG\">HKG: 0512<\/a>), a China-based company, announced on October 26, 2025, that the first patient has been enrolled in the Phase IIa clinical study for its innovative ophthalmic drug, GPN00884, aimed at delaying the progression of myopia in children.<\/p>\n\n\n\n<p><strong>Drug Innovation<\/strong><br>GPN00884 eye drops represent a novel mechanism for delaying pediatric myopia progression. Unlike low-concentration atropine eye drops, GPN00884 does not cause pupil dilation or associated side effects such as photophobia and decreased accommodation. Its flexible dosing schedule enhances patient compliance.<\/p>\n\n\n\n<p><strong>Market Need<\/strong><br>Currently, there is a significant unmet clinical need in China for effective and safe treatments to delay myopia progression in children, a gap that GPN00884 aims to address.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102600006_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025102600006_c.\"><\/object><a id=\"wp-block-file--media-fcf01ba6-0596-4bf8-8d56-71a9d1acb101\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102600006_c.pdf\">2025102600006_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102600006_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fcf01ba6-0596-4bf8-8d56-71a9d1acb101\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44647,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,683,1184,44,68],"class_list":["post-44640","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-grand-pharmaceutical","tag-hkg-0512","tag-ophthalmology","tag-pediatric-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that the first patient has been enrolled in the Phase IIa clinical study for its innovative ophthalmic drug, GPN00884, aimed at delaying the progression of myopia in children.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44640\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression\" \/>\n<meta property=\"og:description\" content=\"Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that the first patient has been enrolled in the Phase IIa clinical study for its innovative ophthalmic drug, GPN00884, aimed at delaying the progression of myopia in children.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44640\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T15:49:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T15:49:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2714.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression\",\"datePublished\":\"2025-10-27T15:49:24+00:00\",\"dateModified\":\"2025-10-27T15:49:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640\"},\"wordCount\":128,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2714.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Grand Pharmaceutical\",\"HKG: 0512\",\"Ophthalmology\",\"Pediatric drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44640#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44640\",\"name\":\"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2714.webp\",\"datePublished\":\"2025-10-27T15:49:24+00:00\",\"dateModified\":\"2025-10-27T15:49:25+00:00\",\"description\":\"Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that the first patient has been enrolled in the Phase IIa clinical study for its innovative ophthalmic drug, GPN00884, aimed at delaying the progression of myopia in children.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44640\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2714.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2714.webp\",\"width\":1080,\"height\":608,\"caption\":\"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44640#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression - Insight, China&#039;s Pharmaceutical Industry","description":"Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that the first patient has been enrolled in the Phase IIa clinical study for its innovative ophthalmic drug, GPN00884, aimed at delaying the progression of myopia in children.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44640","og_locale":"en_US","og_type":"article","og_title":"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression","og_description":"Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that the first patient has been enrolled in the Phase IIa clinical study for its innovative ophthalmic drug, GPN00884, aimed at delaying the progression of myopia in children.","og_url":"https:\/\/flcube.com\/?p=44640","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-27T15:49:24+00:00","article_modified_time":"2025-10-27T15:49:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2714.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44640#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44640"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression","datePublished":"2025-10-27T15:49:24+00:00","dateModified":"2025-10-27T15:49:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44640"},"wordCount":128,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44640#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2714.webp","keywords":["Clinical trial approval \/ initiation","Grand Pharmaceutical","HKG: 0512","Ophthalmology","Pediatric drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44640#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44640","url":"https:\/\/flcube.com\/?p=44640","name":"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44640#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44640#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2714.webp","datePublished":"2025-10-27T15:49:24+00:00","dateModified":"2025-10-27T15:49:25+00:00","description":"Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that the first patient has been enrolled in the Phase IIa clinical study for its innovative ophthalmic drug, GPN00884, aimed at delaying the progression of myopia in children.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44640#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44640"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44640#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2714.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2714.webp","width":1080,"height":608,"caption":"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44640#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2714.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44640"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44640\/revisions"}],"predecessor-version":[{"id":44648,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44640\/revisions\/44648"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44647"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}